Genome-wide Association Study (GWAS) For Juvenile-onset Myopia And Its Component Measures To Identify Molecular Pathways To Prevent Myopia
Funder
National Health and Medical Research Council
Funding Amount
$495,364.00
Summary
We will examine 2,000 young adults from the Western Australian Raine Cohort at the Lions Eye Institute / University of Western Australia. Ocular data will be collected relating to myopia (short-sightedness) and will be combined with extensive previous childhood and genetic research data collected on the Cohort, to investigate the genetic and environmental factors predisposing to myopia. This will assist in understanding the factors leading to myopia.
Using Pharmacogenetics To Personalize Treatment Outcome To Ranibizumab (Lucentis) For The Eye Disease Age-related Macular Degeneration (AMD)
Funder
National Health and Medical Research Council
Funding Amount
$623,891.00
Summary
The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.
Retinal Ganglion Cell Bioenergetics With Clinical Translation
Funder
National Health and Medical Research Council
Funding Amount
$725,913.00
Summary
Glaucoma is an eye disease where elevated pressure within the eye damages the sensitive nerve of sight at the back of the eye. The only current treatment is to lower the pressure in the eye with either drops, laser or surgery. Why the pressure damages the nerve of sight is unclear but there is evidence that it results in a reduced blood flow to the nerve. This starves the nerve of nutrients. We have developed a new treatment that supplies nutrients to the nerve and protects vision.
A Nanosecond Laser Based Surgical Treatment To Prevent Progression To Vision Loss In Early Age-related Macular Degeneration (AMD)
Funder
National Health and Medical Research Council
Funding Amount
$813,481.00
Summary
We aim to conduct a trial of a new nano-laser based treatment for Age-related Macular Degeneration (AMD) which, if successful in slowing progression of AMD, will lead to a dramatic reduction in vision loss in our community. AMD is the leading cause of irreversible vision loss in people 50 years and older in Australia. The successful outcome will postpone vision loss, benefiting many thousands of Australians, and result in substantial healthcare savings.